Smith & Nephew plc (LON:SN)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank AG in a research report issued to clients and investors on Monday, May 15th, StockTargetPrices.com reports. They currently have a GBX 1,200 ($15.18) price target on the stock. Deutsche Bank AG’s price target indicates a potential downside of 12.47% from the stock’s current price.
SN has been the topic of several other research reports. J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,260 ($15.94) price target on shares of Smith & Nephew plc in a research report on Monday, February 6th. Morgan Stanley restated an “overweight” rating and issued a GBX 1,301 ($16.46) price target on shares of Smith & Nephew plc in a research report on Friday, February 10th. Credit Suisse Group restated a “neutral” rating and issued a GBX 1,190 ($15.05) price target on shares of Smith & Nephew plc in a research report on Wednesday, February 8th. Berenberg Bank restated a “hold” rating and issued a GBX 1,340 ($16.95) price target on shares of Smith & Nephew plc in a research report on Wednesday, January 18th. Finally, Jefferies Group LLC dropped their price target on Smith & Nephew plc from GBX 1,370 ($17.33) to GBX 1,350 ($17.08) and set a “buy” rating on the stock in a research report on Friday, February 10th. Ten analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Smith & Nephew plc currently has an average rating of “Hold” and an average price target of GBX 1,279.58 ($16.19).
Smith & Nephew plc (LON SN) traded up 2.08% during trading on Monday, reaching GBX 1371.00. The company’s stock had a trading volume of 4,599,207 shares. Smith & Nephew plc has a 12-month low of GBX 1,064.91 and a 12-month high of GBX 1,377.00. The firm’s 50-day moving average price is GBX 1,329.67 and its 200 day moving average price is GBX 1,238.34. The company’s market capitalization is GBX 11.99 billion.
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.